Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
Study Details
Study Description
Brief Summary
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 690 patients across approximately 60 sites in the United States, Canada and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of ABP-450 utilizing the Company's novel injection paradigm.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
The Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 690 patients across approximately 60 sites in the United States, Canada and Australia from Phase 2 trial. Study subjects who had their initial dose of study drug in Phase 2 trial study, irrespective of treatment allocation, will be eligible to enroll in this extension study. Study subjects will be divided evenly across a group receiving a low dose of ABP-450 and a group receiving a high dose of ABP-450. All patients will receive four treatment cycles utilizing the Company's novel treatment paradigm involving fewer injections than the current botulinum toxin treatment option for chronic migraine.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ABP-450 - Low Dose ABP-450 Low Dose - intramuscular injections into specified muscles. |
Drug: ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Other Names:
|
| Experimental: ABP-450 - High Dose ABP-450 High Dose - intramuscular injections into specified muscles |
Drug: ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of Treatment Emergent Adverse Events [Baseline to Week 52 - End of Study]
The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with ABP-450 (low dose) or ABP-450 (high dose).
- Change in Monthly Migraine Days [Baseline to Week 48 - End of Treatment Period]
The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from Baseline to Weeks 48.
Secondary Outcome Measures
- Percentage of Patients with Reduction in Mean Migraine Days (MMD) [Baseline to Week 52 - End of Study]
Percentage of patients with a reduction from Baseline of ≥ 50 percent, ≥ 75 percent and 100% percent in average number of MMD will be assessed by Treatment Group.
- Mean change in Monthly Migraine Days (MMD) requiring medications for acute treatment of migraine or headaches [Baseline to Week 52 - End of Study]
Overall mean change from Baseline in number of MMD requiring migraine specific medication and non-specific medications for the acute treatment of migraine or headache will be assessed by Treatment Group.
- Mean change in Headache Hours [Baseline to Week 52 - End of Study]
Overall mean change from Baseline in headache (either moderate or severe) hours will be assessed by Treatment Group.
- Mean Change in Monthly Headache Days [Baseline to Week 52 - End of Study]
Overall mean change from Baseline in monthly headache days will be assessed by Treatment Group.
- Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS) [Baseline to Week 52 - End of Study]
Percentage of Participants with Suicidal Ideation and Behaviors will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) with the suicidal ideation on a 5-point scale, ranging from "wish to be dead" to "activesuidical ideatikon with specific plan and intert" and suicidal behaviors of a 4-point scale ranging from "preparatory acts or behavior" to "actual attempt" in lifetime, past 3 months, and since last visit. The higher total scores indicate more suicidal ideation and /or suicidal behavior.
- Development of Anti-Drug Antibodies (ADA) to ABP-450 [Baseline to Week 52 - End of Study]
Percentage of patients developing Anti-Drug Antibodies to ABP-450 antibodies (binding and if positive, neutralizing) will be assessed.
Other Outcome Measures
- Mean change of Migraine-Specific-Quality of Life (MSQ) Domains [Through study completion, an average of 12 months]
The Mean Change in Migraine-Specific-Quality of Life (MSQ), a14-item assessment, with each item rated on a 6-point scale (ranging from "none of the time" to "all of the time") with higher scores indicating better quality of life will be assessed by Treatment Group.
- Mean Change in Patient Global Impression of Change (PGI-C) Score [Baseline to Week 52 - End of Study]
The Mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale with 1-item scale ranging from "much better"k to "much worse" with the higher score indicating worsening of symptoms will be assessed by Treatment Group.
- Mean Change in Patient Global Impression of Severity (PGI-S) Score [Baseline to Week 52 - End of Study]
The Mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale with 1-item scale ranging from "normal" to "severely ill" with the higher score indicaating greater severity in illness will be assessed by Treatment Group.
- Mean Change in Migraine Disability Assessment Score (MIDAS) Total Score [Baseline to Week 52 - End of Study]
The Mean Change in the Migraine Disability Assessment Scale (MIDAS) between Baseline and End of Treatment assessed by Treatment Group. MIDAS is a 5-item self-administered questionnaire. The 5 items sum to a total MIDAS score of 0 to 155. A higher score indicates greater headache-related disability (worse score).
- Percentage of Patients with Reduction in Migraine Physical Function Impact Diary (MPFID) [Baseline to Week 52 - End of Study]
Percentage of patients with a reduction from Baseline in the impact on Migraine Physical Function Impact Diary (MPFID) will be assessed by Treatment Group with an 8-item scale ranging from "without difficulty" to "extremely difficult". The higher the score represents the highest level of impact.
- Percentage of Patients with Reduction in the Physical Impairment Domaine Score of the Migraine Physical Function Impact Diary (MPFID) [Baseline to Week 52 - End of Study]
Percentage of patients with a reduction from Baseline on Physical Impairment Domain Score measured by Migraine Physical Function Impact Diary (MPFID) assessed by Treatment Group with a 5-item scale ranging from "none of the time" to "all of the time" or :without any difficulty" to extreemely difficult". The higher the score represents the highest level of impat
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient can understand the ICF, provides signed ICF and patient privacy information (eg, Authorization for Use and Release of Health and Research Study Information) before initiating any study-specific procedure, and agrees to comply with protocol requirements.
-
Patient was enrolled in Study ABP-20001 and successfully completed that study's treatment and procedures.
-
A WOCBP must be willing and able to use a medically acceptable and effective method of birth control, as determined by the investigator, during the entire study (Appendix 13.3).
-
A WOCBP (Appendix 13.3) must have a negative urine pregnancy test at Visit 1.
-
Patient can read, understand, and complete the eDiary.
-
Patient is willing and able to adhere to the study assessments, visit schedules, and prohibitions, as described in this protocol.
Exclusion Criteria:
-
Did not meet eligibility criteria for Study ABP-20001 and was improperly enrolled or randomized in that study.
-
Failure to successfully complete the Study ABP-20001, including the following:
-
use of prohibited medications
-
delay of >4 weeks in receiving second Study ABP-20001 investigational study drug injection
-
completing fewer than 75% of eDiary entries during the 28-week treatment and follow-up period
-
7 or more consecutive missed days of eDiary entries Note: if the investigator determines that any of the above 4 failures occurred due to extenuating circumstances, patients may be allowed to enroll in Study ABP-20002 if the investigator expects the problem will not recur.
Medical Conditions:
-
History of migraine accompanied by diplopia or decreased level of consciousness, or retinal migraine.
-
Current diagnosis of chronic tension-type headache, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or cranial neuropathy.
-
Confounding and clinically significant pain syndromes (eg, fibromyalgia, chronic low back pain, complex regional pain syndromes) as evaluated by the investigator.
-
Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease that might interfere with the study.
-
Psychiatric conditions that are uncontrolled and/or untreated as evaluated by the investigator.
-
Lifetime history of psychosis, mania, or dementia.
-
History of addiction, including alcohol or drug abuse since initiating ABP-20001 study treatment.
-
Any infection or clinically significant skin problem in any of the injection sites.
-
Any medical condition (including but not limited to viral or other active infections) that, in the opinion of the investigator, classifies the patient as unsuitable for participation in the study or patients who do not seem to be in good general health at the time of signing the informed consent, and prior to any investigational study drug administration.
Note: Patients will not routinely be tested for COVID-19 during the study. Patients presenting with fever or who are symptomatic for COVID-19 will be required to be tested and treated through their general practitioner.
Other Diagnostic Assessments:
- Significant risk of self-harm based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; patients must be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS) in the time since enrolling in Study ABP-20001.
Prior/Concomitant Medications and Treatments
-
Injection with anesthesia or steroids in the targeted muscles since initiating ABP-20001 study treatment.
-
Use of opioids or barbiturates >2 days per month since initiating ABP-20001 study treatment.
-
Use of CBD or other types of cannabinoids since initiating ABP-20001 study treatment.
-
Use of botulinum toxin at or above the shoulders other than ABP-20001 study treatment since initiating ABP-20001 study treatment.
-
Any CGRP inhibitor treatment (eg, erenumab [Aimovig®], eptinezumab [Vyepti™], fremanezumab [Ajovy®], or galcanezumab [Emgality®], rimegepant sulfate [Nurtec™], ubrogepant [Ubrelvy™] within or outside of a clinical study) since initiating ABP-20001 study treatment.
-
Use of small molecule migraine drugs (eg, beta blockers, anticonvulsants, antidepressants, calcium channel blockers) since initiating ABP-20001 study treatment.
-
Use of devices for the treatment of migraine (ie, non-invasive neuromodulation therapies including but not limited to non-invasive nerve stimulation [gammaCore], transcranial magnetic stimulation [cephaly], external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation) since initiating ABP-20001 study treatment.
-
Any other treatments or therapies (eg, acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) to the head, neck, or shoulder regions since initiating ABP-20001 study treatment that, in the opinion of the investigator, would interfere with the investigational study drug.
-
History of inadequate response to 3 classes of medications (which have different mechanisms of action) prescribed for the prevention of migraine, excluding CGRP therapies.
-
History of hypersensitivity to human serum albumin, sucrose, or botulinum toxin type
-
Participation in another interventional study since initiating ABP-20001 study treatment. Other Exclusion Criteria:
-
Patients who have been infected with COVID-19 for whom the infection worsened their migraine disorder. Patients for whom infection with COVID-19 did not worsen their migraine disorder may be included in the study.
-
Female patients pregnant or planning on becoming pregnant during the study and/or lactating/breastfeeding.
-
Patient is an employee or family member of the investigator, study site personnel, PPD, or AEON.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MDFirst Research | Chandler | Arizona | United States | 85226 |
| 2 | Elite Clinical Studies, LLC | Phoenix | Arizona | United States | 85018 |
| 3 | Arizona Neuroscience Research | Phoenix | Arizona | United States | 85032 |
| 4 | Axiom Research LLC | Colton | California | United States | 92324 |
| 5 | Los Angeles Headache Center | Los Angeles | California | United States | 90067 |
| 6 | Anderson Clinical Research | Redlands | California | United States | 92374 |
| 7 | Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS | San Diego | California | United States | 92103 |
| 8 | Delta Waves LLC - Hunt - PPDS | Colorado Springs | Colorado | United States | 80918 |
| 9 | Coastal Connecticut Research, LLC - ClinEdge - PPDS | New London | Connecticut | United States | 06320 |
| 10 | Community Research of South Florida | Hialeah | Florida | United States | 33016 |
| 11 | Canvas Clinical Research | Lake Worth | Florida | United States | 33467 |
| 12 | BioMed Research Institute, INC | Miami | Florida | United States | 33126 |
| 13 | Medical Research Center, LLC | Miami | Florida | United States | 33144 |
| 14 | Renstar Medical Research | Ocala | Florida | United States | 34470 |
| 15 | Innovation Medical Research Center | Palmetto Bay | Florida | United States | 33157 |
| 16 | Clinical Research of Central Florida - ClinEdge - PPDS | Winter Haven | Florida | United States | 33810 |
| 17 | NeuroTrials Research Inc. - Clinedge - PPDS | Atlanta | Georgia | United States | 30328 |
| 18 | Drug Studies America, Inc | Marietta | Georgia | United States | 30060 |
| 19 | Velocity Clinical Research - Boise - ERN - PPDS | Meridian | Idaho | United States | 83642 |
| 20 | Kansas Institute of Research, LLC | Overland Park | Kansas | United States | 66211 |
| 21 | Legacy Clinical Solutions: Tandem Clinical Research, LLC - Clinedge - PPDS | Marrero | Louisiana | United States | 70072 |
| 22 | Boston Clinical Trials Inc | Boston | Massachusetts | United States | 02131 |
| 23 | Quest Research Institute - Hunt - PPDS | Farmington Hills | Michigan | United States | 40825 |
| 24 | StudyMetrix Research, LLC | Saint Peters | Missouri | United States | 63303 |
| 25 | Clinvest Research LLC | Springfield | Missouri | United States | 65810 |
| 26 | Barrett Clinic, P.C. - Clinedge - PPDS | La Vista | Nebraska | United States | 68128 |
| 27 | Quality Clinical Research | Omaha | Nebraska | United States | 68114 |
| 28 | Wake Research - CRCN, LLC | Las Vegas | Nevada | United States | 89104 |
| 29 | Albuquerque Clinical Trials Inc - Clinedge - PPDS | Albuquerque | New Mexico | United States | 87102 |
| 30 | Dent Neurologic Institute | Amherst | New York | United States | 14226 |
| 31 | Upstate Clinical Research Associates LLC | Williamsville | New York | United States | 14221 |
| 32 | The Orthopedic Foundation | New Albany | Ohio | United States | 43054 |
| 33 | Preferred Primary Care Physicians | Pittsburgh | Pennsylvania | United States | 15236 |
| 34 | DCT - Baxter LLC dba Discovery Clinical Trials | Dallas | Texas | United States | 75225 |
| 35 | Mercury Clinical Research Incorporated | Sugar Land | Texas | United States | 77478 |
| 36 | Aspen Clinical Research LLC - Clinedge - PPDS | Orem | Utah | United States | 84058 |
| 37 | Northwest Clinical Research Center | Bellevue | Washington | United States | 98004 |
Sponsors and Collaborators
- AEON Biopharma, Inc.
- PPD
Investigators
- Principal Investigator: Richard B Lipton, MD, Albert Einstein College of Medicine
- Principal Investigator: Stewart J Tepper, MD, Dartmouth-Hitchcock Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ABP-20002